Johnson & Johnson $JNJ Shares Sold by Connecticut Wealth Management LLC

Connecticut Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,012 shares of the company’s stock after selling 508 shares during the period. Connecticut Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,655,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in JNJ. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $50,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ opened at $177.10 on Friday. The stock has a fifty day moving average of $165.99 and a 200-day moving average of $160.01. The firm has a market capitalization of $426.52 billion, a P/E ratio of 18.94, a PEG ratio of 2.23 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Finally, Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.